Hememics Biotechnologies

Executive Summary

Hememics Biotechnologies is a privately held, US-based diagnostics company focused on developing portable, rapid diagnostic devices using its proprietary FAST™ (Functionalized Analyte Screening Technology) platform. The platform integrates microfluidic chips with monolayer graphene to enable immunoassay-based detection of pathogens and antibodies, delivering digital results faster and at lower cost than conventional lab methods such as ELISA. Founded in 2015 and headquartered in Rockville, Maryland, the company aims to address the need for point-of-care diagnostics in settings where speed, affordability, and objectivity are critical. Despite the promising technology, limited public information is available regarding funding, revenue, or clinical validation, which introduces uncertainty regarding commercial readiness. Hememics operates in the competitive in vitro diagnostics market, with potential applications in infectious disease testing, food safety, and biodefense. Its graphene-based sensor technology offers advantages in sensitivity and multiplexing capability, potentially enabling simultaneous screening of multiple targets. However, the company's stage, valuation, and total funding are undisclosed, and no commercial products are yet on the market. If the platform achieves regulatory clearance and secures strategic partnerships, it could disrupt traditional lab-based testing. Investors should monitor for progress in clinical trials, regulatory submissions, and partnerships that validate the technology’s real-world utility.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) clearance or Emergency Use Authorization for a flagship diagnostic test40% success
• Q2 2026Strategic partnership or distribution agreement with a larger diagnostics company50% success
• Q3 2026New funding round (Series A or B) to support commercialization45% success